drugset
drugset / Trial / NCT01060514

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

NCT01060514 ↗

Phase 1 Terminated 8 enrolled Northwestern University Robert H. Lurie Cancer Center · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects. Also, this study will evaluate what effects (good and bad) that the treatment has on patients and their cancer.

Timeline

Start
2010-02
Primary completion
2012-02
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule — Oral
Subject Vinorelbine Small molecule — Intravenous

Indications

breast cancer non-small cell lung carcinoma